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Targeted drug delivery is of major current interest to medicine, 
specifically in oncology.1,2 The design of drugs capable of crossing 
cell membranes is the main problem in this field.3 The current 
synthesis of pharmacologically active compounds involves the 
formation of hybrid molecular structures4,5 or molecular con­
jugates6–11 with different combinations of pharmacophoric func­
tions and properties.12,13
Amphiphilic compounds with spatially separated hydrophilic 
and lipophilic fragments tend to exhibit membranotropic activity. 
Thus, there are great prospects in the modification of natural pro­
ducts, especially isoprenoids.14–16 Furthermore, isoprenoid hydro­
 carbon frame structures have found application as membrane anchors 
in the design of modulators for membrane­integrated proteins.17,18 
Therefore, we hypothesized that the introduction of bio­
logically active fragments into terpenoid hydrocarbon structures 
may lead to their targeted delivery into subcellular compartments. 
To verify this hypothesis, we synthesized amphiphilic compounds 
containing a terpenoid hydrocarbon chain. Our aim was to deter­
mine how different hydrophilic fragments in terpenoid derivatives 
affect their ability to interact with a phospholipid membrane. 
Based on monoterpene b­myrcene, we prepared compounds con­
taining carboxyl (2), carboxylate (3) and tertiary ammonium (6) 
groups using the Diels–Alder click reaction between N­sub sti­
tuted maleimides 1 and 5 and b­myrcene (Scheme 1).†
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The title drug delivery compounds with pharmacophoric moieties were synthesized, and their interaction with model biomembranes 
(dipalmitoylphosphatidylcholine vesicles) was examined.
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 2-[5-(4-Methylpent-3-en-1-yl)-1,3-dioxo-3a,4,7,7a-tetrahydro-1H-iso-
indol-2(3H)-yl]acetic acid 2. Imide 1 (0.20 g, 1.3 mmol) was dissolved 
in 5 ml of THF. Then 0.34 ml (2.0 mmol) of myrcene was added to this 
solu tion. The mixture was left overnight at room temperature. There after, 
THF was removed in a vacuum and the solid residue was recrys tallized 
from n­hexane to yield 0.28 g (74%) of compound 2, mp 84­85 °C. 1H NMR 
(CDCl3) d: 1.59 (s, 3 H, Me), 1.68 (s, 3 H, Me), 2.03 (m, 4 H, CH2), 2.26 
(m, 2 H, CH2), 2.56 (m, 2 H, CH2), 3.17 (ddd, 2 H, CH, 3JHH 9.2 Hz, 
3JHH 6.3 Hz, 3JHH 3.4 Hz), 4.25 [s, 2 H, C(O)CH2N], 5.03 (br. s, 1H, =CH), 
5.57 (br. s, 1H, =CH). 13C NMR (CDCl3) d: 17.7, 24.0, 25.7, 25.9, 27.5, 
37.2, 39.2, 39.5, 39.8, 119.8, 123.6, 131.9, 140.2, 171.5, 179.2, 179.4. 
IR (n/cm–1): 1748, 1676 (C=O), 2728, 2601, 2520 (COOH). MS (MALDI­
TOF), m/z: 291.9 [M + H]+, 313.8 [M + Na]+ (calc. for [M+], m/z 291.2). 
Found (%): C, 65.72; H, 7.07; N, 5.10. Calc. for C16H21NO4 (%): C, 65.96; 
H, 7.27; N, 4.81.
 Sodium 2-[5-(4-methylpent-3-en-1-yl)-1,3-dioxo-3a,4,7,7a-tetrahydro-
1H-isoindol-2(3H)-yl]acetate 3. Sodium (0.1 g, 4.30 mmol) was added  to 
the solution of compound 2 (0.10 g, 0.34 mmol) in 5 ml of abs. THF. The 
mixture was stirred for 6 h and then filtered. The filtrate was evaporated 
and solvent traces were removed in a high vacuum. Yield of compound 3 
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Scheme 1 Reagents and conditions: i, b­myrcene, THF, 12 h; ii, abs. THF, 
Na, 6 h; iii, MeCN, MeI, 20 °C.
was 0.10 g (93%). 1H NMR (DMSO­d6) d: 1.54 (s, 3 H, Me), 1.62 (s, 3 H, 
Me), 1.91 (m, 4 H, CH2), 1.98 (m, 2 H, CH2), 2.16 (m, 2 H, CH2), 2.30 (m, 
2 H, CH2), 3.06 (ddd, 2 H, CH, 3JHH 9.1 Hz, 3JHH 6.0 Hz, 3JHH 3.0 Hz), 
3.56 (s, 2H, CH2), 4.97 (br. s, 1H, =CH), 5.47 (br. s, 1H, =CH). 13C NMR 
(DMSO­d6) d: 22.8, 28.7, 30.6, 30.7, 31.2, 32.2, 42.1, 43.7, 44.2, 47.7, 125.1, 
129.0, 136.0, 144.6, 173.5, 184.7, 184.8. MS (MALDI­TOF), m/z: 313.8 
[M + H]+, 335.8 [M + Na]+ (calc. for [M+], m/z 313.1). Found (%): C, 61.10; 
H, 6.34; N, 4.54. Calc. for C16H20NNaO4 (%): C, 61.33; H, 6.43; N, 4.47.
 N,N-Diethyl-N-methyl-2-[5-(4-methylpent-3-en-1-yl)-1,3-dioxo-3a,4, 
7,7a-tetrahydro-1H-isoindol-2(3H)-yl]ethanaminium iodide 6. Myrcene 
(5 ml, 29.4 mmol) was added to the solution of compound 5 (0.3 g, 0.88 mmol) 
in 20 ml of THF. The mixture was left at room temperature for 24 h. 
Thereafter, THF was removed in a vacuum and the solid residue was 
recrystallized from ethyl acetate to yield 0.35 g (83%) of compound 6, 
mp 99–100 °C. 1H NMR (CDCl3) d: 1.44 (t, 6 H, Me, 3JHH 7.25 Hz), 1.58 
(s, 3 H, Me), 1.66 (s, 3 H, Me), 2.00 (m, 4 H, CH2), 2.21 (m, 2 H, CH2), 2.53 
(m, 2 H, CH2), 3.28 (ddd, 2 H, CH, 3JHH 9.3 Hz, 3JHH 6.9 Hz, 3JHH 2.2 Hz), 3.32 
(s, 3 H, +N–Me), 3.69 (m, 6 H, +N–CH2), 3.89 (t, 2 H, CH2N, 3JHH 7.2 Hz), 
5.00 (br. s, 1H, =CH), 5.53 (br. s, 1H, =CH). 13C NMR (CDCl3) d: 8.5, 
17.8, 23.9, 25.7, 26.1, 27.3, 32.4, 37.4, 39.6, 40.0, 48.4, 56.7, 57.7, 120.0, 
123.4, 132.1, 140.5, 179.9, 180.0, 181.7. IR (n/cm–1): 1767, 1695 (C=O). 
MS (MALDI­TOF), m/z: 346.7 [M – I]+ (calc. for [M+]: m/z 474.2). 
Found (%): C, 52.92; H, 7.32; N, 6.09; I, 26.69. Calc. for C21H35IN2O2 (%): 
C, 53.16; H, 7.44; N, 5.90; I, 26.75.
